|
Title
|
|
|
|
Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Background: Panitumumab in combination with chemotherapy was evaluated in two pivotal clinical trials in first- and second-line treatment of metastatic colorectal cancer (mCRC), respectively. This analysis compared the health-related quality of life (HRQoL) of patients with or without panitumumab in the two trials. Methods: Patients with mCRC were randomised to FOLFOX (first-line trial) or FOLFIRI (second-line trial)±panitumumab. The EuroQoL 5-Dimensions Health State Index (EQ-5D HSI) and Visual Analogue Scale (EQ-5D VAS) were assessed at baseline and monthly follow-up until disease progression. Patients with wild-type KRAS mCRC with baseline and post-baseline HRQoL scores were included. Difference in change from baseline between treatment groups was evaluated using linear mixed and pattern-mixture models. Results: In the first-line trial, 576 patients with wild-type KRAS mCRC (284 panitumumab+FOLFOX4 and 292 FOLFOX4 alone) were included in the HRQoL analyses. In the second-line trial, 530 patients with wild-type KRAS mCRC were included in these analyses (263 panitumumab+FOLFIRI and 267 FOLFIRI alone). There was no significant difference in the change in EQ-5D HSI and VAS scores between treatment groups in either trial. Conclusion: The addition of panitumumab to FOLFOX4 or FOLFIRI in first- or second-line treatment of wild-type KRAS mCRC significantly improved progression-free survival without compromising HRQoL. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
The British journal of cancer. - London
|
|
|
Publication
|
|
|
|
London
:
2011
|
|
|
ISSN
|
|
|
|
0007-0920
|
|
|
DOI
|
|
|
|
10.1038/BJC.2011.409
|
|
|
Volume/pages
|
|
|
|
105
:10
(2011)
, p. 1495-1502
|
|
|
ISI
|
|
|
|
000296794200005
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|